US › Healthcare

Marker Therapeutics Inc (MRKR)

US · Healthcare · Biotechnology

$1.23+0.82%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Revenue YoY
-100.0%
Net profit
$-3.2M
Profit YoY
+28.5%
EPS
$-0.16
EPS estimate
$-0.19

EPS came in at -0.16 against a street estimate of -0.19 — a beat of 15.8%.

Key statistics

Market cap
$18.8M
Forward P/E
0.0
P/B
1.36
Book value
$0.83
EPS (TTM)
$-0.55
52-week high
$2.46
52-week low
$0.81
50-day MA
$1.39
200-day MA
$1.40
Beta
1.45

Analyst view

Analysts rate Marker Therapeutics Inc a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $7.87.

Shareholding

Insiders
5.49%
Institutions
23.71%

Largest institutional holders

FundStake
NEA Management Company, LLC9.75%
Blue Owl Capital Holdings LP3.32%
Vanguard Capital Management, LLC2.33%
Aisling Capital Management LP1.95%
Renaissance Technologies Corp1.05%
Geode Capital Management, LLC0.97%
Advisor Group Holdings, Inc.0.56%
Vanguard Fiduciary Trust Co0.52%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Marker Therapeutics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.